← Leaderboards
Seth H. Pincus
Montana State University (Bozeman)
$5,449,944
Attributed
$7,548,018
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $834.7K · FY2005–22$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
Funding mix
By agency
NIH$7,548,018 · 9
By mechanism
R01$5,478,073 · 3
R56$745,291 · 1
R21$554,130 · 1
R42$387,448 · 1
P51$243,076 · 2
R03$140,000 · 1
Top collaborators
- Robert D. Harrington5 shared
- Chad J Roy1 shared
Most similar at Montana State University (Bozeman)
Same institution · by research overlap
- Benfang Lei$3,821,802
Others in their field
Top investigators on “Laboratory Mouse”
- Richard K. Wilson · Washington University$122,948,010
- Frank Patrick McCormick · University Of California San Francisco$87,382,096
- David Heimbrook · Leidos Biomedical Research, Inc.$81,904,667
- Kc Kent Lloyd · University Of California At Davis$56,148,943
- Alfred G Gilman · University Of Texas Sw Med Ctr/Dallas$53,869,943
- Carol J Bult · Jackson Laboratory$47,860,052
Research focus
Laboratory MouseAntibodiesIn VivoToxinDrug Screening /EvaluationCellsBaseSiteHiv InfectionsTissuesRicinMonoclonal AntibodiesImmunoconjugatesAffectMediatingCytotoxic AgentComplement ReceptorComparative EfficacyCytotoxicCytotoxicityAntiviral TherapyAntiviral AgentsAntigen Antibody ReactionAntiretroviral Therapy
Grant awards (25)
Cytotoxic immunoconjugates to deplete persistent HIV reservoirs$709,073
R01 · FY2022 · AI · contact PI
Cytotoxic immunoconjugates to deplete persistent HIV reservoirs$834,696
R01 · FY2021 · AI · contact PI
Cytotoxic immunoconjugates to deplete persistent HIV reservoirs$632,663
R01 · FY2020 · AI · contact PI
Cytotoxic immunoconjugates to deplete persistent HIV reservoirs$625,098
R01 · FY2019 · AI · contact PI
Cytotoxic immunoconjugates to deplete persistent HIV reservoirs$649,327
R01 · FY2018 · AI · contact PI
In Vivo Mechanisms of Antibody-mediated Protection from Aerosolized Ricin Toxin$745,291
R56 · FY2017 · AI · contact PI
Mechanisms of Antibody-Mediated Toxin Neutralization$290,530
R01 · FY2008 · AI · contact PI
Mechanisms of Antibody-Mediated Toxin Neutralization$436,891
R01 · FY2007 · AI · contact PI
Mechanisms of Antibody-Mediated Toxin Neutralization$489,550
R01 · FY2006 · AI · contact PI
Furin Inhibition in HIV Disease$125,129
R21 · FY2006 · AI · contact PI
Mechanisms of Antibody-Mediated Toxin Neutralization$357,500
R01 · FY2005 · AI
Furin Inhibition in HIV Disease$214,500
R21 · FY2005 · AI
ANTI-HIV IMMUNOTOXINS$54,500
P51 · FY2005 · RR
Mechanisms of Antibody-Mediated Toxin Neutralization$23,209
R01 · FY2005 · AI
Mechanisms of Antibody-Mediated Toxin Neutralization$214,729
R01 · FY2004 · AI
Furin Inhibition in HIV Disease$203,176
R21 · FY2004 · AI
Mechanisms of Antibody-Mediated Toxin Neutralization$64,851
R01 · FY2004 · AI
ANTI-HIV IMMUNOTOXINS$47,161
P51 · FY2004 · RR
Furin Inhibition in HIV Disease$11,325
R21 · FY2004 · AI
IN VIVO ACTIVITY OF ANTI-GP41 IMMUNOTOXINS$141,415
P51 · FY2003 · RR
HIV INFECTIVITY TEST FOR ANTIVIRAL SUSCEPTIBILITY$141,987
R42 · FY2001 · CA
ROLE OF MURINE LEUKEMIA VIRUS IN AUTOIMMUNITY$70,000
R03 · FY2001 · AI
HIV INFECTIVITY TEST FOR ANTIVIRAL SUSCEPTIBILITY$245,461
R42 · FY2000 · CA
PEPTIDE MIMETICS OF STREPTOCOCCAL CARBOHYDRATE ANTIGENS$149,956
R01 · FY2000 · AI
ROLE OF MURINE LEUKEMIA VIRUS IN AUTOIMMUNITY$70,000
R03 · FY2000 · AI